EGFR and non-small cell lung carcinoma: In our previous published research, we used HIF-1 inhibitor and activator to regulate the activity of the HIF-1 pathway and found that HIF-1 inhibitor can enhance the sensitivity of HCC827 cells (EGFR-TKIs sensitive EGFR exon 19 mutant NSCLC cell line) to EGFR-TKIs [13].